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Abstract
In December 2019, an outbreak of novel coronavirus started in Wuhan, China, which gradually
spread to the entire world. The World Health Organization (WHO) on February 11, 2020,
officially announced the name for the disease as coronavirus disease 2019, abbreviated as
COVID-19. It is caused by severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2).
The WHO declared SARS-CoV-2 as a pandemic on March 11, 2020. SARS-CoV-2 mainly causes
fever as well as respiratory symptoms such as cough and shortness of breath.
Gastrointestinal/hepatic sequelae such as diarrhea, nausea, vomiting, and elevated liver
enzymes have been reported as well. Studies and data so far on coronavirus infections from
China, Singapore, and other countries showed that liver enzymes elevation could be seen in 2050% of cases. More severe disease can correlate with the worsening of liver enzymes. However,
acute liver failure in patients with COVID-19 has not been described. Herein we report a case
of acute liver failure in an elderly patient with COVID-19 infection who did not have a history
of preexisting liver disease.
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Until recently, seven types of coronaviruses had been reported to cause infections in
humans [1]. Coronaviruses can use animal hosts and then can evolve to infect humans. This
process is thought to explain the emergence of SARS-CoV (severe respiratory distress syndrome
coronavirus) in 2003, MERS-CoV (Middle Eastern Respiratory Syndrome) in 2012, and SARSCoV-2 in 2019. SARS-CoV-2 has 82% genome sequence similarity to SARS-CoV and 50%
genome sequence homology to MERS-CoV. COVID-19 symptoms range from mild (fever, cough,
or dyspnea) to moderate (respiratory failure requiring oxygen support) and can progress to
ARDS (acute respiratory distress syndrome) and multiorgan failure. In one of the earlier
studies, 80% of cases were mild, but the mortality rate ranged from 1.86% to 9.86% [2]. Higher
mortality rates were reported in countries like Italy, possibly secondary to resource depletion in
an overwhelmed health care system. Gastrointestinal symptoms such as diarrhea have been
reported in approximately 2-10% of patients [3], with a lower rate in China (3.7%) as compared
to Singapore (17%) [4]. Liver injury has been reported in 60% of patients with SARS-CoV [5] and
has also been reported in patients infected with MERS-CoV [6]. Studies also suggest that SARSCoV-2 can affect the liver [7-9]. In a recent study published in Shanghai, 75 (50.7%) out of 148
patients were found to have elevated liver enzymes with SARS-CoV-2 [7]. In another study
published in the Lancet in February 2020 by Huang et al., an increase in aspartate
aminotransferase (AST) was observed in 62% in intensive care unit (ICU) patients compared to
25% in non-ICU patients, indicating that more severe disease correlates with worsening of liver
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enzymes [10]. Several other studies showed that liver injury in the form of an increase in
AST/alanine aminotransferase (ALT) levels with a mild increase in bilirubin ranging from 14.8%
to 53% [11]. In patients who died of SARS-CoV-2, liver injury was reported as high as
58.06% [12]. The highest levels recorded included an ALT of 7,590 U/L and an AST of 1,445
U/L [13]. Generally speaking, transaminase elevations are mild in patients with COVID-19.
Here, we report a case of acute liver failure in an elderly patient with COVID-19 infection who
did not have a history of preexisting liver disease.

Case Presentation
An 80-year-old male with a medical history of diabetes, hypertension, dyslipidemia, asthma,
coronary artery disease with bypass graft, atrial fibrillation on warfarin, and heart failure with
preserved ejection fraction with an automatic implantable cardiac defibrillator and pacemaker
presented to the emergency department (ED) in March 2020 with intermittent fever, productive
cough, and shortness of breath (SOB) for four to five days. He initially started noticing fever
that was partially relieved by acetaminophen five days prior to presentation (maximum
temperature of 102°F at home). This was associated with SOB on exertion, which progressed to
SOB at rest and a productive cough. He denied any recent travel, contact with sick person,
herbal medications use, or a recent change in home medications. His home medications
included oral warfarin daily, oral metoprolol tartrate two times daily, oral metformin ER daily,
oral aspirin daily, oral atorvastatin, and budesonide-formoterol inhaler twice daily. The review
of systems was otherwise negative. The patient did not have a history of smoking, alcohol
consumption, illicit drugs, or high-risk sexual behavior. Vitals at the time of admission showed
a temperature of 101.6°F, heart rate of 80 beats/minute, blood pressure 140/70 of mm Hg,
respiratory rate of 20 breaths/minute, and oxygen saturation of 98% on room air. Physical
examination was positive for bilateral wheeze and rhonchi in all lung fields, 1+ pedal edema
bilateral. His chest was without spider angiomas and abdomen with no hepatosplenomegaly,
and he had no shifting dullness, with normoactive bowel sounds and no palmar erythema. On
neurological examination, he was alert, oriented to time, place/person, followed commands,
and had no focal deficits. Laboratory examination results are shown in Table 1.
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Laboratory results

Day 0

WBC count

2.20 (normal: 4.8-10.8 K/uL)

RBC count

2.75 (normal: 4.7-6.1 M/uL)

Hemoglobin

10.4 (normal: 14-18 g/dL)

Hematocrit

30.2 (normal: 42-52%)

Platelet count

74 (normal: 13-400 K/uL)

Lymphocyte

1.03 (normal: 1.2-3.4 K/uL)

Serum total protein

6.3 (normal: 6.0-8.0 mg/dL)

Serum albumin

3.7 (normal: 3.5-5.2 mg/dL)

Serum total bilirubin

0.5 (normal: 0.2-1.2 mg/dL)

Serum alkaline phosphatase

78 (normal: 30-115 U/L)

Aspartate aminotransferase

34 (normal: 0-41 U/L)

Alanine aminotransferase

14 (normal: 0-41 U/L)

eGFR

52 (normal: ≥60 mL/min/1.73 m2)

Creatinine kinase

754 (normal: 0-225 U/l)

TABLE 1: Laboratory results
WBC, white blood cell; RBC, red blood cell; eGFR, estimated glomerular filtration rate

The patient had normal liver enzymes at presentation but had elevated transaminases on day 4.
The examination at that time was negative for asterixis or encephalopathy. Atorvastatin was
stopped, and the recommendation was made to start N acetylcysteine (NAC), and workup for
acute and chronic liver disease was ordered. His respiratory status continued to deteriorate,
requiring increased oxygen support. His radiologic findings worsened with enlarging infiltrates
on a chest X-ray on day 4, as shown in Figures 1-3.
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FIGURE 1: Day 1: portable chest X-ray showing bilateral
interstitial infiltrates

FIGURE 2: Day 4: portable chest X-ray showing worsening
bilateral interstitial infiltrates
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FIGURE 3: Day 7: progressive worsening bilateral infiltrates

On day 5, the patient changed his status to do not resuscitate or intubate after the goals of care
conversation. He also refused further interventions, including ultrasound abdomen, liver
biopsy, or NAC. Progression of the patient’s vital signs and laboratory results are shown in
Tables 2, 3.

Vital signs

Day 0

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

Temperature (°F)

101.6

97.8

103.1

102.1

99.7

96.7

98.7

96.2

93.5

BP (mm Hg)

140/70

150/68

138/62

144/62

152/72

140/93

141/93

142/82

99/55

HR (beats/min)

80

69

68

62

86

64

64

60

63

RR (per min)

20

18

18

22

22

26

28

22

26

Saturation (%)

98% RA

97% RA

97% RA

97% 2 liters NC

93% 5 liters NC

93% on the venti mask 50%

97% on NRB

90% on NRB

88% on NRB

TABLE 2: Vital signs
BP, blood pressure; HR, heart rate; RR, respiratory rate; RA, room air; NC, NC, nasal cannula; NRB, non-rebreather mask
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Laboratory results

Day 0

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

WBC count (4.8-10.8 K/uL)

2.20

1.27

5.80

3.85

5.35

8.28

--

10.99

16.27

RBC count (4.7-6.1 M/uL)

2.75

2.38

2.98

2.67

2.60

2.61

--

2.95

3.15

Hemoglobin (14-18 g/dL)

10.4

9.0

10.7

9.9

9.6

9.6

--

10.8

10.9

Hematocrit (42-52%)

30.2

27.8

32.3

28.8

28.3

28.9

--

31.5

33.1

Platelet count (13-400 K/uL)

74

55

90

92

83

49

--

76

66

Lymphocyte (1.2-3.4 K/uL)

1.03

0.93

1.65

1.49

1.36

1.22

--

0.63

1.02

Serum total protein (6.0-8.0 mg/dL)

6.3

6.4

6.7

6.2

6.2

6.3

--

6.4

6.6

Serum albumin (3.5-5.2 mg/dL)

3.7

3.6

3.8

3.4

3.4

3.4

--

3.3

3.3

Serum total bilirubin (0.2-1.2 mg/dL)

0.5

0.3

0.4

0.6

1.2

3.4

--

5.2

8.4

Serum alkaline phosphatase (30-115 U/L)

78

71

70

107

145

322

--

357

358

Aspartate aminotransferase (0-41 U/L)

34

27

43

95

3223

>7000

--

2619

1361

Alanine aminotransferase (0-41 U/L)

14

13

14

37

1553

3737

--

2588

1989

Gamma glutamyltransferase (0-41 U/L)

eGFR (≥60 mL/min/1.73 m 2)

158

52

63

52

52

47

INR

2.54

1.88

1.59

1.87

Fibrinogen (mg/dL) (204-570)

>700

Procalcitonin (0.02-0.10 ng/mL)

0.88

Ferritin (30-400 ng/mL)

436

2.66

--

19

11

--

5.05

8.94

1.16

3.07

TABLE 3: Laboratory results during subsequent hospitalization
WBC, white blood cell; RBC, red blood cell; eGFR, estimated glomerular filtration rate; INR, international normalized ratio

On day 6, he was disoriented to time and place, his physical examination was positive for
asterixis, and international normalized ratio (INR) began to rise on day 7 and day 8 despite the
fact that coumadin was held on day 1. The patient was hypertensive until day 8 when his blood
pressure dropped to 99/55 mm Hg. The clinical picture was suggestive of acute liver failure.
Transfer to live transplant center was not attempted per the family’s request. Tylenol level was
<5 (normal: 10-30 ug/mL); other biochemical tests for acute and chronic liver disease are
shown in Table 4.
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Viral panel

Hepatitis A IgM antibody

Non-reactive

Hepatitis B surface Ag

Non-reactive

Hepatitis B surface Ab

Non-reactive

Hepatitis B core IgM Ab

Non-reactive

Hepatitis C Ab

Non-reactive

HSV-1 IgM Ab

Non-reactive

HSV-1 IgG Ab

Positive

HSV-2 IgM Ab

Non-reactive

HSV-2 IgG Ab

Non-reactive

EBV IgM Ab

Non-reactive

CMV PCR

Non-reactive

HIV PCR

Non-reactive

Autoimmune and metabolic panel

ANA

<1:20

AMA

<1:20

ASMA

<1:20

Anti-LKM 1 Ab

<20 (normal: 0-20 units)

IgA

442 (normal: 84-499 mg/dL)

IgM

106 (normal: 35-242 mg/dL)

IgG

1148 (normal: 610-1160 mg/dL)

Serum iron

236 (normal: 35-150 ug/dL)

TIBC

253 (normal: 220-430 ug/dL)

Ferritin

436 (normal: 30-400 ng/mL)

Ceruloplasmin

36 (normal: 15-30 mg/dL)

TABLE 4: Transaminitis workup
Ig, immunoglobulin; Ag, Ag; AB, antibody; HSV herpes simplex virus; EBV, Epstein-Barr virus; CMV, cytomegalovirus; PCR, polymerase
chain reaction; HIV human immunodeficiency virus; ANA, antinuclear antibodies; AMA, antimitochondrial antibodies; ASMA, antismooth
muscle antibodies; LKM, liver kidney microsomal; TIBC, total iron-binding capacity
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The patient then developed cytokine release syndrome (CRS) (elevated interleukin [IL]-6 and IL10 as mentioned in Table 5), and he expired on day 9.

Cytokine markers

IL-6

59 (normal: 0-15.5 pg/mL)

IL-10

18.1 (normal: <2 pg/mL)

IL-2

<31 (normal: 0-31.2 pg/mL)

IL-17

<5 (normal: <13 pg/mL)

IFN gamma

23 (normal: <5 pg/mL)

TABLE 5: Cytokine markers
IL, interleukin; IFN, interferon

Discussion
COVID-19 is a pandemic illness that primarily affects the respiratory system with a wide
spectrum of disease presentation that ranges from mild disease (fever, cough) to severe (ARDS,
multiorgan failure). The gastrointestinal/hepatic systems are the next most commonly affected,
with symptoms such as nausea, vomiting, diarrhea, and an increase in liver enzymes. Currently,
studies on the exact pathophysiology of liver injury in these patients are limited, but it is
believed either to be a direct effect of the virus or immune-mediated inflammatory response,
such as CRS, hypoxemia, and failure of innate immune regulation, or to be drug-induced.
1) It is postulated that both SARS-CoV-2 and SARS-CoV bind to angiotensin-converting
enzyme 2 (ACE2) receptors to enter the target cell [14] where the virus replication begins and
starts to infect cells of the upper respiratory tract. Based on the scRNA-seq data, Chai et
al. [15] found that ACE 2 receptors also found in the hepatobiliary system (high in bile duct
cells, cholangiocytes, when compared to liver cells). Cholangiocytes play a critical role in liver
regeneration and immune responses [16]. Thus, the authors concluded that potential damage
of cholangiocytes by 2019-nCoV might lead to profound consequences in the liver rather than
the direct effect of the virus on hepatocytes.
2) CRS is a group of disorders caused by a wide variety of inflammatory etiologies, resulting in a
profound increase in inflammatory markers such as IL-2, IL-7, IL-6 granulocyte colonystimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1,
macrophage, inflammatory protein 1-α, and tumor necrosis factor-α. This can ultimately lead
to hemodynamic instability, multiorgan dysfunction, and death [17]. Elevations in IL-6, IL-10,
procalcitonin, and ferritin, as well as thrombocytopenia have been associated with severe
COVID and potentially severe liver injury as seen in our patient [18].
3) Ischemic hepatitis, also known as shock liver, is characterized by a significant increase in
serum aminotransferases due to reduced oxygen delivery to the liver, usually seen in shock and
thromboembolic disease [19].
4) Clinicians should also consider drug-induced liver injury due to hepatotoxicity associated
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with drugs used in treating COVID such as lopinavir, ritonavir, and hydroxychloroquine that are
recently approved by the FDA for the treatment of COVID.
Our patient, who had no previous history of liver disease and normal liver enzymes at
presentation, developed elevated liver enzyme levels on day 4. Initial differential diagnosis was
broad, including ischemic hepatitis, drug-induced liver injury, viral hepatitis, cholestasis of
sepsis, and autoimmune diseases. On laboratory workup, viral infections such as hepatitis (A, B,
C), Epstein-Barr virus, cytomegalovirus, herpes simplex virus, HIV, autoimmune, and metabolic
causes were ruled out. Since his blood pressure was stable until day 8 of his hospitalization
without any pressor support, ischemic hepatitis was unlikely [20]. Tylenol toxicity was excluded
(levels were less than 5 ug/mL).
The remainder of the patient’s medications were reviewed, and none of the patient’s
medications was likely to be the culprit. For example, the patient’s home medication coumadin
is a rare cause of acute liver injury and usually results in a cholestatic pattern rather than a
hepatocellular one, which is what our patient demonstrated. Aspirin has been associated with
an increase in liver enzymes but usually only with dosages of more than 1,800 to 3,200 mg
daily. Metoprolol and metformin have been associated with only mild elevations in liver
enzymes. Hydroxychloroquine used to treat SARS-CoV-2 has been rarely associated with
clinically apparent liver injury. A single case series (two cases) of acute liver failure attributed
to hydroxychloroquine was published, but these patients took the medication for more than
two weeks.

Conclusions
In summary, we describe the first case of acute liver failure caused by the COVID-19 infection.
Acute liver failure was diagnosed clinically by rising liver function tests and INR, as well as
progressive encephalopathy. We could not conclusively prove that the COVID-19 was the
etiologic agent as the patient declined a liver biopsy. However, alternative causes of acute liver
failure were effectively ruled out. Bloodwork did not identify another etiology, and the patient’s
hypotension was too late in his course and too mild to cause ischemic hepatopathy.
Additionally, none of his medications was among the usual suspect for acute liver failure. As we
learn more about this new infection, we expect to better understand the spectrum,
pathophysiology, and treatment of the resultant liver injury.
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